Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

ClinicalTrials.gov ID: NCT00274261

Public ClinicalTrials.gov record NCT00274261. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II/III Multicenter, Randomized, Double-masked, Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of contraception over six months (183 days) and at least six cycles of use. In addition, there is an opportunity for subjects to continue with study treatment for up to twelve months (365 days) and twelve cycles of treatment upon completion of the first six months of treatment.

Study identification

NCT ID: NCT00274261
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Premier Research; Other
Enrollment: 1,565 participants

Conditions and interventions

Conditions

Pregnancy

Interventions

C31G Drug
nonoxynol-9 (N-9) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 40 Years
Sex: Female
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2004
Primary completion: Jun 30, 2008
Completion: Aug 31, 2008
Last update posted: Apr 30, 2018

2004 – 2008

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
California Family Health Council	Berkeley	California	94710	—
California Family Health Council	Los Angeles	California	90010	—
University of Colorado - Advanced reproductive Medicine	Aurora	Colorado	80010	—
Johns Hopkins Bayview Medical Center	Baltimore	Maryland	21224	—
Bay State Medical Center	Springfield	Massachusetts	01199	—
New York University	New York	New York	10016	—
Columbia University	New York	New York	10032	—
University of Cincinnati	Cincinnati	Ohio	45267	—
University Hospitals of Cleveland MacDonald Women's Hospital	Cleveland	Ohio	44106	—
The Ohio State University College of Medicine	Columbus	Ohio	43210	—
Oregon Health & Science University	Portland	Oregon	97239	—
University of Pennsylvania Medical Center	Philadelphia	Pennsylvania	19104	—
University of Pittsburgh	Pittsburgh	Pennsylvania	15213	—
U.T. Southwestern Medical Center	Dallas	Texas	75390	—
Jones Institute of Reproductive Medicine, EVMS	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00274261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2018 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00274261 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →